Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Porfimer
Drug ID BADD_D01802
Description The purified component of hematoporphyrin derivative, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of photodynamic therapy in the United States.
Indications and Usage Indicated in the treatment of esophageal cancer.
Marketing Status approved; investigational
ATC Code L01XD01
DrugBank ID DB00707
KEGG ID D03327
MeSH ID D017323
PubChem ID 135577896
TTD Drug ID D02JDL
NDC Product Code 76128-155
UNII M15H03K69B
Synonyms Dihematoporphyrin Ether | Ether, Dihematoporphyrin | Dihematoporphyrin Ester | Porfimer | DHP Ether | Porfimer Sodium | Photofrin | Photofrin II
Chemical Information
Molecular Formula C68H74N8O11
CAS Registry Number 87806-31-3
SMILES CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)O)C)C(=C4C)C(C)OC(C)C6=C(C7=CC 8=C(C(=C(N8)C=C9C(=C(C(=N9)C=C1C(=C(C(=N1)C=C6N7)C)CCC(=O)O)CCC(=O)O)C)C)C(C)O)C )C(=C3CCC(=O)O)C)CCC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemorrhage24.07.01.002---
Post procedural complication12.02.05.018---
Angiopathy24.03.02.007---
Cardiac disorder02.11.01.003---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Infestation11.09.01.001; 23.11.01.002---
Inflammation08.01.05.007; 10.02.01.089---
Malnutrition14.03.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
Porphyrin metabolism disorder03.08.01.006; 09.01.10.004; 14.14.01.006---
Decreased appetite08.01.09.028; 14.03.01.005--
Carcinoma in situ16.16.01.006---
Blood disorder01.05.01.004---
Obstruction08.01.03.023---
Oesophageal neoplasm07.21.04.004; 16.13.08.001---
Increased bronchial secretion22.12.01.002---
Oesophageal oedema07.11.02.002---
Procedural pain08.01.08.009; 12.02.05.007---
Bronchial secretion retention22.03.02.008---
Regurgitation07.01.07.004---
Skin mass23.07.04.014---
Candida infection11.03.03.021--
Sinus node dysfunction02.03.03.017--
The 5th Page    First    Pre   5    Total 5 Pages